Targeting platelet activation and aggregation is an important component of acute coronary syndrome (ACS) management. Numerous new agents that target platelets have been approved, but the risks of bleeding with these agents must be balanced against their benefits. Practice guidelines provide evidence-based recommendations for managing antiplatelet therapy, both short term and long term.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Managed Care Medicine|
|State||Published - 2014|
ASJC Scopus subject areas
- Health Policy